| Margins | Blended margins expected to rise 2-3% as premium production scales. |
|---|---|
| Order book | 3-4 months visibility for premium products. |
| Demand visibility | Strong; roughly 4,000 MT order book on hand. |
| Management confidence | High confidence in premium product demand and technology R&D edge. |
Growth
FY26 sales reached 15,000 MT, exceeding 10,000 MT installed capacity through trading. H2 revenue grew on premium product mix.
Outlook
Unit 3 Phase 1 (CCS/CMC) expected by June 2026; Phase 2 (MCC) by March 2027. Phase 3 planned for 2028.
Risks
Regulatory delays in Unit 3 commercialization; potential impact of new labor laws on domestic unit profitability.
Earnings Call filed with NSE, NSE: ACCENTMIC. Summary written with AI assistance from the document.
Accent Microcell Ltd: key numbers
- Share price
- ₹674.85
- Market cap
- ₹1,619 Cr
- Revenue (annual)
- ₹349.0 Cr
- Net profit (annual)
- ₹43.86 Cr
- P/E (TTM)
- 36.9×Sector 50.4×
- Promoter holding
- 53.02%-2.45% QoQ
- FII holding
- 0.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accent Microcell Ltd
All →Accent Microcell Earnings Call: Key Takeaways
Accent Microcell reported FY26 revenue of ₹34,903 Lakhs (up 31.92% YoY) and PAT of ₹4,385 Lakhs (up 32.65% YoY), driven by strong export growth and expansion in pharmaceutical excipients.
Accent Microcell Earnings Call: Key Takeaways
Accent Microcell delivered record H2 results driven by a strategic shift toward premium products like MCC spheres, though Unit 3 delays at Navagam remain a point of concern for immediate scaling.
Accent Microcell H2 FY26 Results: Net Profit ₹25.8 Cr, Up 55.4% YoY
Accent Microcell Ltd reported revenue from operations of ₹209.7 Cr (+51.4% YoY) and net profit of ₹25.8 Cr (+55.4% YoY) for H2 FY26.
- Key figure
- Net profit ₹25.8 Cr · +55.4% YoY